Key facts

Active substance
Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain, A/H3N2-like strain, B-like strain (Victoria lineage) and B-like strain (Yamagata lineage)
Therapeutic area
Infectious diseases
Decision number
PIP number
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of influenza infection
Route(s) of administration
Intramuscular use
Contact for public enquiries
Sanofi pasteur

Email: piplan@sanofipasteur.com
Tel. +33 4373 75038

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)


How useful was this page?

Add your rating